Abstract:
Background: Cancer immunotherapy, particularly Immune Checkpoint Inhibitors (ICIs), has revolutionized oncology. However, its implementation in developing and conflict-affected regions faces severe structural and economic challenges. This study evaluates the current landscape, barriers, and opportunities for cancer immunotherapy in Lebanon, Sudan, and Iraq.
Methods: A descriptive and analytical cross-sectional survey was conducted among oncology professionals (n=23) actively practicing in Lebanon, Sudan, and Iraq. Data regarding institutional infrastructure, drug availability, financial toxicity, patient access, and clinical outcomes were gathered and analyzed to identify critical implementation gaps.
Results: Preliminary findings reveal a stark disparity between clinical guidelines and real-world accessibility. Major implementation barriers include prohibitive out-of-pocket costs, lack of public healthcare funding, disrupted supply chains, and specialized infrastructure deficits. In conflict-affected zones like Sudan and Iraq, healthcare instability further exacerbates treatment interruptions. Conversely, Lebanon displays higher baseline clinical awareness but suffers from severe economic-driven resource shortages. Despite these barriers, substantial opportunities exist in establishing regional collaborative networks, optimizing generic biosimilar pathways, and leveraging digital health for remote expert consultation.
Conclusion: Implementing cancer immunotherapy in the Levant and Sub-Saharan regions requires transitioning from idealized global protocols to resource-stratified consensus guidelines. Addressing financial toxicity and stabilizing supply chains through international partnerships are imperative to bridge the equity gap in global oncology.
Keywords: Cancer Immunotherapy, Implementation Barriers, Financial Toxicity, Sudan, Iraq, Lebanon, Resource-Stratified Oncology.
Biography:
To be updated shortly..
Copyright 2024 Mathews International LLC All Rights Reserved
